Profile: Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)
17 Jun 2019
Corbus Pharmaceuticals Holdings, Inc. incorporated on December 18, 2013, is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
The Company competes with Vertex, PTC Therapeutics, UK CF Gene Therapy Consortium, Novartis, Bayer, Nivalis Therapeutics, Flatley Discovery Lab, Galapagos/AbbVie, ProQR, Celtaxsys, Proteostasis, Roche, Boehringer Ingelheim, Bristol Myers, Sanofi, Promedior and Digna Biotech.
Corbus Pharmaceuticals Holdings Inc
100 River Ridge Dr
NORWOOD MA 02062-5030